Sirpiglenastat, also known as DRP-104, is a prodrug of 6-diazo-5-oxo-L-norleucine (DON), a broad-acting glutamine antagonist. It is under investigation in clinical trials for advanced solid tumors.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 2079939-05-0
Hexarelin acetate
pharmaceutical raw material
Digoxin
pharmaceutical raw material
Daunorubicin
pharmaceutical raw material
Micafungin sodium
pharmaceutical raw material
propan-2-yl (2S)-2-[[(2S)-2-acetamido-3-(1H-indol-3-yl)propanoyl]amino]-6-diazo-5-oxohexanoate
LQNMCWOJACNQQM-PMACEKPBSA-N
CC(C)OC(=O)[C@H](CCC(=O)C=[N+]=[N-])NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C